Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $543 from $541 and keeps an Outperform rating on the shares. Shares have been weak recently, with perceptions of higher risk near-term catalyst path, but getting through decent Q1 results with high expressed operational confidence for the rest of 2026 and reaffirmation of pove’s clean safety is a good start towards clearing the overhangs, the analyst tells investors in a research note.